Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review. [version 2; peer review: 1 approved, 2 approved with reservations]

Ahmad Farouk Musa¹, Xian Pei Cheong¹, Jeswant Dillon², Rusli Bin Nordin¹

¹Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia
²Department of Cardiothoracic Surgery, National Heart Institute, Kuala Lumpur, Malaysia

Abstract

Background: The European System for Cardiac Operative Risk (EuroSCORE) II was developed in 2011 to replace the aging EUROScore for predicting in-house mortality after cardiac surgery. Our aim was to validate EuroSCORE II in Malaysian patients undergoing coronary artery bypass graft (CABG) surgery at our Institute.

Methods: A retrospective single-center study was performed. A database was created to include EuroSCORE II values and actual mortality of 1718 patients undergoing CABG surgery in Malaysia from 1st January to 31st December 2016. The goodness-of-fit of EuroSCORE II was determined by the Hosmer-Lemeshow goodness-of-fit test and discriminatory power with the areas under the receiver operating characteristics (ROC) curve (AUC).

Results: Observed mortality rate was 4.66% (80 out of 1718 patients). The median EuroSCORE II value was 2.06% (Inter Quartile Range: 1.94%) (1st quartile: 1.45%, 3rd quartile: 3.39%). The AUC for EuroSCORE II was 0.7 (95% CI 0.640 – 0.759) indicating good discriminatory power. The Hosmer-Lemeshow goodness-of-fit test did not show significant difference between expected and observed mortality in accordance to the EuroSCORE II model (Chi-square = 13.758, p = 0.089) suggesting good calibration of the model in this population. Cross-tabulation analysis showed that there is slight overestimation of EuroSCORE II in low-risk groups (0-10%) and slight underestimation in high-risk groups (>20%). Multivariate logistic regression analysis showed that gender, age, total hospital stay, serum creatinine and critical pre-operative state are significant predictors of mortality post-CABG surgery.

Conclusion: This study indicated that the EuroSCORE II is a good
predictor of post-operative mortality in the context of Malaysian patients undergoing CABG surgery. Our study also showed that certain independent variables might possess higher weightage in predicting mortality among this patient group. Therefore, it is suggested that EuroSCORE II can be safely used for risk assessment while ideally, clinical consideration should be applied on an individual basis.

**Keywords**
EuroSCORE II, predictor, coronary artery bypass graft, post-CABG mortality, National Heart Institute

**Corresponding author:** Ahmad Farouk Musa (farouk@monash.edu)

**Author roles:** Musa AF: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Validation, Writing – Review & Editing; Cheong XP: Data Curation, Formal Analysis, Validation, Writing – Original Draft Preparation; Dillon J: Data Curation, Project Administration, Resources, Supervision, Visualization; Nordin RB: Formal Analysis, Project Administration, Supervision, Validation, Visualization

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2019 Musa AF et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Musa AF, Cheong XP, Dillon J and Nordin RB. Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review. [version 2; peer review: 1 approved, 2 approved with reservations] F1000Research 2019, 7:534 https://doi.org/10.12688/f1000research.14760.2

**First published:** 02 May 2018, 7:534 https://doi.org/10.12688/f1000research.14760.1
Amendments from Version 1

Firstly, we have rearranged the sequence of statistics according to countries. The correct sequence will be as followed: The mortality rate for Italy, Greece and Serbia will be 4.85%, 3% and 3.7% respectively.

Further details were provided on the details of weight of intervention including isolated CABG procedures, two procedures (CABG + Aortic Valve Replacement (AVR), CABG + Mitral Valve Replacement (MVR), CABG + Aortic Root Replacement) and three procedures (CABG + MVR + AVR, CABG + Atrial Septal Defect (ASD) + Devega’s Tricuspid Annuloplasty). Furthermore, due to the fact that there is a gross mismatch between expected and observed mortalities among the >20% predicted risk group extra details on weightage of intervention were provided on the 8 patients who died in this particular risk group.

Following that, among this particular group of patients with different weightage of intervention (isolated procedure, 2 procedures and 3 procedures), subgroup analysis was performed on in-hospital mortality rate and performance of EuroSCORE II in predicting mortality (discriminatory power based on ROC curve analysis) as well as its calibration among the local population as depicted by Hosmer and Lemeshow Goodness-of-Fit test.

Any further responses from the reviewers can be found at the end of the article.

Introduction

Coronary Artery Bypass Grafting (CABG) surgery, being a major surgery, is not without significant risks, up to and including death. In the United States, operative death rate and in-hospital mortality rate post CABG between 1997 and 2001 ranged from 1% to 5% for all patients. In Malaysia, statistics from the National Heart Institute (IJN) had shown that the mortality rate for patients undergoing CABG surgery in Malaysia was around 2.7%. Notwithstanding, it is important to take note that the associated risk is very much dependent on multiple interacting factors including patients’ comorbidities and occurrence of any complications due to the operation itself.

The need for a simple tool to predict post-surgical mortality led to the development of the European System for Cardiac Operative Risk Evaluation (EuroSCORE), also known as the European System for Cardiac Operation Risk Evaluation in 1999. This is a risk evaluation tool to calculate and predict operative mortality in patients undergoing cardiac surgery. It was developed using risk factors collected from almost 20,000 patients from more than 100 hospitals in Europe.

Since the publication of EuroSCORE, it had been widely employed and validated in various populations of cardiac surgical patients. However, it was found that the additive score for EuroSCORE tended to underestimate the risk of mortality, possibly when there were co-existing risk factors in high-risk patients. These concerns led to the development of the more complicated logistic EuroSCORE I. This version did produce a better estimate of risk in high risk patients. However, its main drawback is the overestimation of risk despite improvements in cardiac surgical outcomes observed.

In order to overcome this issue, the EuroSCORE team has come up with a revised version, which is known as the EuroSCORE II during the 2011 EACTS meeting in Lisbon. EuroSCORE II was developed by collecting and analysing prospective risk and outcome data on 22,381 patients undergoing major cardiac surgery in 154 hospitals in 43 countries over a 12-week period (May–July 2010). The new EuroSCORE II has updated the definition of renal function and unstable angina. Also, it further subdivided the classification of pulmonary hypertension, urgency and weight of operation. Most importantly, the new model has also changed the definition of outcome measurement, from 30-day mortality rate to in-hospital mortality. The main reason was the loss of follow-up data after discharge in certain centres, thereby giving rise to poor quality data in the original EuroSCORE.

Throughout the years, multiple validation studies have been conducted around the world including Europe, America and Asia to examine the validity of EuroSCORE II in predicting post-operative mortality and it had shown different results regarding the discriminatory power and calibration of this scoring system in different populations.

Furthermore, the EuroSCORE II has yet to be validated in Malaysia, a country with high incidence of cardiovascular diseases. Therefore, this study will serve as the first in Malaysia to examine the validity of EuroSCORE II in predicting operative mortality among patients undergoing CABG surgery.

Methods

Study design

A single-centre retrospective review was conducted at the National Heart Institute (IJN), the largest heart center in Malaysia. Almost all of the information needed was retrieved from the IJN electronic in-house database. Out-of-hospital data including death and late complications was obtained via telephone enquiry.

Ethical statement

Ethical approval was obtained from both the IJN Research Ethics Committee (IJNREC/238/2018) and Monash University Human Research Ethics Committee (MUHREC/12981). The study was also registered with the National Medical Research Register (NMRR-17-2749-39322).

Study sample

Within the period from 1st January 2016 to 31st December 2016, 1718 consecutive patients undergoing CABG surgery at the IJN were included in this study.

Inclusion Criteria: All patients undergoing CABG including two or three procedures.

Exclusion Criteria: Reinterventions for any cause in the same admission as the primary operation.

Measurements

EuroSCORE II included ten patient-related factors, five cardiac-related factors, and three operation-related factors. Patient related factors include age (year), gender (male/female), renal impairment (creatinine clearance), extracardiac arteriopathy,
poor mobility, previous cardiac surgery, chronic lung disease, active endocarditis, critical preoperative state and diabetes on insulin. Cardiac related factors include the New York Heart Association (NYHA) stages, Canadian Cardiovascular Society (CCS) class 4 angina, Left Ventricular (LV) function (ejection fraction > 50%, 31-50%, 21-30%, <20%), recent myocardial infarction (MI) (within 90 days) and pulmonary hypertension (31-55 mm Hg / >55 mm Hg). Operation related factors include urgency (elective, urgent, emergency, salvage), weight of the intervention (isolated CABG, isolated single non-CABG, 2-procedures, 3-procedures) and surgery on thoracic aorta. Details regarding EuroSCORE II calculation are available from the EuroSCORE site. The outcome variable, which is in-hospital mortality, was retrieved from the in-hospital database. In other words, it simply means death occurring at any time after surgery during the current admission. Additionally, important clinical information including presence of comorbidities (hypertension and hypercholesterolemia), total hospital stay, total ICU stay and follow-up status were also collected. A database is then created to collect the relevant data and stored in spreadsheets.

**Statistical analysis**

Data was evaluated using the Microsoft Excel 2016 database (Microsoft Inc.) and analyzed using the Statistical Package for Social Sciences (SPSS) version 23.0. Continuous variables were presented as mean and standard deviation. Categorical variables were presented as frequencies and compared between groups using the chi-square test. A multiple logistic regression analysis was undertaken to determine significant predictors of in-hospital mortality. Predictive ability of the estimation model was assessed through discriminatory power and calibration. Receiver operating characteristics (ROC) curve analysis was performed to estimate the discriminant ability of this risk scoring model in predicting immediate post-operative mortality. It was considered good if the area under the curve (AUC) was >0.70. Calibration was evaluated using the Hosmer-Lemeshow goodness-of-fit test.

**Results**

**Patients’ backgrounds**

The demographics and pre-operative characteristics of patients are shown in Table 1. In terms of social demographics, mean age was 60 ± 8.89 years old, women made up 15.9% of the total sample, and Malay constituted the largest ethnic group (53.8%), which corresponds to the race distribution in Malaysia. Majority of the patients had comorbidities such as hypertension (83.3%) and hypercholesterolemia (77.4%). Preoperatively, the majority of patients were in NYHA class I (41.2%) and II (49.9%). Majority (46.6%) had good left ventricular function. Intraoperatively, majority of patients underwent isolated CABG (86.6%) without previous history of cardiac surgery (98.7%). In terms of weight of intervention, there are 160 patients who underwent a combination of two procedures, which included CABG + AVR, CABG + MVR as well as CABG + Aortic Root Replacement. For 33 patients who underwent three procedures, it included CABG+MVR+Aortic Root Replacement; CABG+MVR+AVR; as well as CABG + ASD Closure + Devega’s Tricuspid Annuloplasty.

| Table 1. Patients’ demographics, preoperative and intraoperative variables (n=1718). |
|---------------------------------------------------------------|
| **Variables** | **Value** |
| Age, year; mean ± SD (Range) | 60 ± 8.89 (28 - 88) |
| Gender | |
| Male | 1444 (84.1%) |
| Female | 274 (15.9%) |
| Race | |
| Malay, n (%) | 924 (53.8%) |
| Chinese, n (%) | 373 (21.7%) |
| Indian, n (%) | 333 (19.4%) |
| Others, n (%) | 88 (5.1%) |
| Hypertension, n (%) | 1431 (83.3%) |
| Diabetes Mellitus, n (%) | 968 (56.3%) |
| Diabetes on insulin, n (%) | 349 (20.3%) |
| Hypercholesterolemia, n (%) | 1329 (77.4%) |
| NYHA | |
| NYHA I, n (%) | 707 (41.2%) |
| NYHA II, n (%) | 857 (49.9%) |
| NYHA III, n (%) | 117 (6.8%) |
| NYHA IV, n (%) | 8 (0.5%) |
| Left ventricular function (EF: Ejection Fraction) | |
| EF > 50%, n (%) | 801 (46.6%) |
| EF 31 – 50%, n (%) | 716 (41.7%) |
| EF 21 – 30%, n (%) | 132 (7.7%) |
| EF < 21%, n (%) | 21 (1.2%) |
| Types of CABG | |
| On-pump | 1687 (98.2%) |
| Off-pump | 30 (1.7%) |
| Extracardiac arteriopathy, n (%) | 70 (4.1%) |
| Poor mobility, n (%) | 41 (2.4%) |
| Previous cardiac surgery, n (%) | 22 (1.3%) |
| Chronic lung disease, n (%) | 101 (5.9%) |
| Active endocarditis, n (%) | 7 (0.4%) |
| Critical pre-operative state, n (%) | 81 (4.7%) |
| CCS class IV angina, n (%) | 26 (1.5%) |
| Recent MI, n (%) | 552 (32.1%) |
| Pulmonary hypertension | |
| PA Systolic: < 31mm Hg, n (%) | 1647 (95.9%) |
| PA Systolic: 31 – 55mm Hg, n (%) | 60 (3.5%) |
| PA Systolic: > 55mm Hg, n (%) | 11 (0.6%) |
| Urgency | |
| Elective, n (%) | 1518 (88.4%) |
| Urgent, n (%) | 168 (9.8%) |
| Emergency, n (%) | 32 (1.9%) |
| Salvage, n (%) | 0 (0.0%) |
| Weight of intervention | |
| Isolated CABG, n (%) | 1488 (86.6%) |
| Isolated, single non-CABG, n (%) | 4 (0.2%) |
| Two procedures, n (%) | 160 (9.3%) |
| Three procedures, n (%) | 33 (1.9%) |
| Surgery on thoracic aorta, n (%) | 12 (0.7%) |
| EuroSCORE II; median (range) | 2.06 (0.5 – 45.3) |

n: Number of patients, SD: Standard deviation, CCS: Canadian Cardiovascular Society, MI: Myocardial infarction, NYHA: New York Heart Association, EF: Ejection fraction, CABG: Coronary artery bypass grafting, PA: Pulmonary artery, EuroSCORE: European system for cardiac operative risk evaluation
Observed and predicted in-hospital deaths
The actual in-hospital mortality rate was 4.7% (80 out of 1718 patients). In comparison, predicted mortality rate by the median EuroSCORE II value was 2.06 (1st quartile: 1.452, 3rd quartile: 3.389). In other words, the predicted in-hospital mortality rate was slightly lower compared to the observed mortality rate. The correct classification was seen for 1638 out of 1718 patients, giving rise to a success rate of 95.3%. Actual mortality rate, by quartiles of EuroSCORE II, was 1.6% in the first quartile, 3.0% in the second quartile, 4.7% in the third quartile and 9.4% in the fourth quartile as shown in Table 2.

Discriminatory power
As illustrated in Figure 1, the area under the receiver operating characteristic curve (AUC) was 0.7 (95% CI 0.640 – 0.759, p < 0.001), suggesting that the EuroSCORE II has fair and acceptable discriminatory power to discriminate between incidences of patients who died and those who were alive.

Calibration (predictive power)
The Hosmer-Lemeshow (HL) goodness-of-fit test did not show significant difference between expected and observed mortality in accordance to the EuroSCORE II model (Chi-square: 13.748, p = 0.089), indicating reasonable calibration of this model in predicting in-hospital mortality among patients who underwent CABG surgery. Cross-tabulation analysis of predicted risk by EuroSCORE II showed that there was slight overestimation in low risk group (0 – 10%) and slight underestimation in high risk group (>20%) as shown in Table 3. Among the 8 patients who died in the 11-20% subgroup,

| Outcome | Quartiles of EuroSCORE II |
|---------|---------------------------|
|         | [0 – 1.45] % | [1.46 – 2.05] % | [2.06 – 3.39] % | >[3.39] % |
| Alive   | 422 (98.4%) | 421 (97%) | 408 (95.3%) | 387 (90.6%) |
| Died    | 7 (1.6%) | 13 (3%) | 20 (4.7%) | 40 (9.4%) |
| Total   | 429 | 434 | 428 | 427 |

EuroSCORE: European system for cardiac operative risk evaluation

Figure 1. Receiver operating characteristic (ROC) curve for EuroSCORE II of 1718 CABG patients (Area Under the ROC curve = AUC = 70.0%) EuroSCORE: European system for cardiac operative risk evaluation.
4 of them had isolated CABG (50%), while 2 of them underwent two procedures (25%) and the other 2, three procedures (25%) respectively. Figure 2 shows the relationship between age and EuroSCORE II in patients post-CABG in the IJN, Malaysia.

**Subgroup analysis**

Analysis was subsequently performed based on weightage of procedures. Among 1488 patients who underwent isolated CABG, we observed an actual in-hospital mortality rate of 3.9% and a median EuroSCORE II (predicted mortality) of 1.918, which showed an underestimation of risk. Hosmer and Lemeshow Goodness-of-Fit test showed a significant p value of 0.032, indicating a significant difference between expected and actual mortality among this group of patients. Discriminatory power as shown by the ROC curve analysis showed an area of 67.8%.

Among 160 patients who underwent two procedures, we observed an actual in-hospital mortality rate of 10% and a median EuroSCORE II (predicted mortality) of 3.712, which showed an underestimation of risk. However, Hosmer and Lemeshow Goodness-of-Fit test showed a non-significant p-value of 0.591, indicating no significant difference between expected and actual mortality among this group of patients. Discriminatory power as shown by the ROC curve analysis showed an area of 63.4%.

Lastly, among 33 patients who underwent three procedures, we observed an actual in-hospital mortality rate of 18.2% and a median EuroSCORE II (predicted mortality) of 6.2, which showed an underestimation of risk. Similar to two procedures, Hosmer and Lemeshow Goodness-of-Fit test showed a

| Predicted Risk | Patients who died | Patients who were alive | Total patients |
|---------------|-------------------|-------------------------|---------------|
|               | Observed          | Expected                | Observed      | Expected      |               |
| 0 – 10%       | 67                | 76.9                    | 1585          | 1575.1        | 1652          |
| 11 – 20%      | 5                 | 2.1                     | 40            | 42.9          | 45            |
| >20%          | 8                 | 1                       | 13            | 20            | 21            |

EuroSCORE: European system for cardiac operative risk evaluation

**Figure 2.** Scatter plot of EuroSCORE II of the 1781 CABG patients, by age (in years).
non-significant p-value of 0.575, indicating no significant difference between expected and actual mortality among this group of patients. Discriminatory power as shown by the ROC curve analysis showed an area of 67.9%.

Analysis on discriminatory power were repeated on other subgroups, including gender, race (Malay, Chinese, Indian and others), age (below 60 years old, 60 years old and above) and presence of comorbidities (hypertension, diabetes mellitus and hypercholesterolemia). Subgroup analysis showed that AUC for the EuroSCORE II was 0.695 in male (95% CI 0.620 – 0.770; p < 0.001), 0.642 in female (95% CI 0.534 – 0.751; p = 0.017), 0.696 in Malay (95% CI 0.624 – 0.767; p < 0.001), 0.801 in Chinese (95% CI 0.696 – 0.906; p < 0.001), 0.642 in Indians (95% CI 0.470 – 0.813; p = 0.083), 0.596 in other ethnicities (95% CI 0.153 – 1.000; p = 0.573), 0.700 in those aged below 60 years old (95% CI 0.571 – 0.830; p = 0.006), 0.673 in those age 60 years old and above (95% CI 0.603 – 0.743; p < 0.001), 0.691 in hypertensive patients (95% CI 0.628 – 0.754; p < 0.001), 0.745 in patients without hypertension (95% CI 0.585 – 0.905; p = 0.04), 0.672 in diabetic patients (95% CI 0.602 – 0.741; p < 0.001), 0.728 in patients without diabetes (95% CI 0.614 – 0.841; p < 0.001), 0.683 in patients with hypercholesterolemia (95% CI 0.615 – 0.750; p < 0.001) and 0.768 in patients without hypercholesterolemia (95% CI 0.650 – 0.886; p < 0.001).

Independent variables analysis
Multivariate binary logistic regression analysis was undertaken to develop a prediction model of variables in EuroSCORE II and outcome (in-hospital mortality). The forward conditional method was selected to be used for analysis. The last step showed that being female, aged more than or equal to 65 years old, serum creatinine more than 120 micromole/litre and longer ICU stay are significant and independent predictors of in-hospital mortality in patients undergoing CABG surgery as shown in Table 4. The model which consists of the four risk factors explained between 24.6% (Cox and Snell R-square) and 47.8% (Nagelkerke R-square) of variance (95% CI 0.615 – 0.741, p < 0.001) and 0.768 in patients without hypercholesterolemia (95% CI 0.650 – 0.886, p < 0.001).

Discussion
Accurate prediction of risk is always essential and plays an important role in guiding doctors to make clinical decision as to whether surgery is an appropriate intervention, especially among high risk patients. In the field of cardiothoracic surgical practice, several risk assessment tools or models, including the EuroSCORE II, have been proposed and developed by researchers based on clinical databases selected from specific populations. Concurrently, the EuroSCORE II has become one of the most commonly used risk evaluation tool in many cardiac centres worldwide. However, it is crucial to note that the EuroSCORE II was actually developed based on data from mainly European countries. Therefore, the application of EuroSCORE II in other populations might need cautious clinical consideration as there are other inter-related factors such as genetic background of the population, different healthcare systems as well as different social and cultural practice.

In our present study, we have determined both the calibration and discriminatory power of the EuroSCORE II in our local population undergoing CABG surgery. Calibration of a model includes the determination of its ability to compare the predicted outcome (EuroSCORE II) with the actual outcome (actual in-hospital mortality) in the entire sample. Discriminatory power is the ability of the EuroSCORE II to

| Variables                        | p value | Adjusted Odds Ratio | 95% CI Lower | 95% CI Upper |
|----------------------------------|---------|---------------------|-------------|-------------|
| Age ≥ 65 years                   | 0.015   | 3.381               | 1.273       | 8.984       |
| Female                           | 0.037   | 3.279               | 1.076       | 10.000      |
| Serum Creatinine ≥ 120 µmol/L    | 0.012   | 3.429               | 1.306       | 9.000       |
| ICU stay (day)                   | <0.001  | 4.170               | 3.107       | 5.598       |

Table 4. Multiple logistic regression analysis showing association between age, gender, serum creatinine, and length of intensive care unit (ICU) stay (independent variables) and in-hospital mortality (dependent variable).
distinguish patients who were still alive or who died in the hospital. Results showed that the EuroSCORE II has reasonable and fair calibration and discriminatory power in this group of Malaysian patients who underwent CABG surgery.

Many studies have been conducted around the world to examine the validity of the EuroSCORE II in predicting in-hospital mortality post-CABG. First of all, one of the most important findings in our study will be the in-hospital mortality rate. According to multiple validated studies that had been conducted across Europe, it showed a mortality rate ranging from 4.85%, 3% and 3.7% in Italy, Greece and Serbia, respectively. Consistent with previous literature, we observed an actual in-hospital mortality rate of 4.7% in this study.

A multicentre prospective validation study was done to compare the EuroSCORE and EuroSCORE II among 4000 patients undergoing cardiac surgery in Spain. Results showed that both the EuroSCORE and EuroSCORE II have good discriminatory power (AUC > 0.75). In addition, the original EuroSCORE tends to over-predict mortality while EuroSCORE II under-predict mortality. Similarly, a single centre validation study in Hungary has also shown that EuroSCORE overestimated the risk of mortality while EuroSCORE II underestimated the risk. Despite that, EuroSCORE II was still better than its original version in terms of discriminatory power. Our study results showed a skewed distribution of EuroSCORE II and the median was 2.06 in comparison to the actual mortality rate of 4.7%, which certainly showed underestimation of risk by the EuroSCORE II.

In terms of calibration and discriminatory power, most of the validation studies in Europe including Spain, Italy, Greece, Serbia and Hungary has an AUC of more than 0.7, which indicates good discriminatory power and calibration. However, there was a collaborative study between two centres in the Netherlands and United Kingdom, which showed that EuroSCORE II was not good in predicting mortality in patients undergoing cardiac operation. It showed an unsatisfactory AUC of 0.67, indicating poor discriminatory power. Particularly in middle-eastern countries, a slightly different results were observed. For instance, in Pakistan, it was shown that, despite having a satisfactory discriminatory power, EuroSCORE II was poorly calibrated and the original EuroSCORE actually fared better than the EuroSCORE II among isolated CABG patients in their local population. This can be attributed to various demographic-related factors or even study bias. Among our population of CABG patients, we observed an AUC of 0.7, which is deemed to be satisfactory in predicting in-hospital mortality.

Our study had shown that only female gender, age more than or equal to 65 years old, serum creatinine more than 120 micro-mole/litre and longer ICU stay are significant predictors of in-hospital mortality in patients post CABG surgery. In this context, independent variables were selected in line with the principle of parsimony so that our analysis can be more consistent and limited to as few variables as possible in the prediction model.

According to previous literatures, increasing age was found to be a significant risk factor by a few studies to investigate age as a risk predictor in patients undergoing CABG surgery. In terms of gender, multiple studies had shown that female gender was an independent predictor for early and late mortality after cardiac operation. Chronic renal dysfunction has also been known to have close association with mortality after CABG. After the establishment of EuroSCORE in 2003, a study was performed to look into patients undergoing CABG with a preoperative serum creatinine <200 µmol/L. It was shown that both the in-hospital mortality rate and stroke rate for this group of patients went up to 2.5%. Furthermore, the mortality rate also increased with increasing preoperative serum creatinine level.

Risk prediction is a very important area in cardiothoracic surgery that can serve to further refine the quality of patient care. By taking into consideration a series of relevant risk factors, the predicted risk by EuroSCORE II can guide us as to whether to perform an operation or to treat conservatively certain patients. Given the fact that multiple studies had shown that the original EuroSCORE was outdated and not applicable for risk prediction, EuroSCORE II can replace its predecessor as a risk prediction model for mortality prediction. As discussed previously, a significant number of cardiac centres around the world including Europe, Asia and the Middle-East had validated EuroSCORE II with acceptable results. We believe that it can serve as a practical tool for the benefits of cardiac surgeons in terms of risk analysis, quality assurance as well as cost consideration.

Nonethelss, we do not deny the fact that it is still virtually impossible to develop an ideal risk evaluation model that fits everyone in the world as all of the models were developed based on clinical data from certain region-specific population. Moreover, given that cardiac surgery has gone through major advancement over the years in terms of improvement in surgical techniques and perioperative care, preoperative risk prediction has been shown to be a moving target that is both important and challenging to tackle.

Looking forward, our efforts for improvement will focus on the universality and practicability of the risk evaluation model. First of all, the lack of parsimony is a problem with the EuroSCORE II, which consists of 18 variables. A simpler risk prediction model with fewer variables that is able to predict in-hospital mortality would be better. Should we be able to develop a relatively simpler and straightforward risk model in the future, the aim will be to have it provide the same predictive power but also be more user-friendly. Following that, we also recommend that a multicentre large scale study should be undertaken to incorporate population groups from all over the world with more variation in terms of genetic and social backgrounds so that a universal and culturally sensitive risk assessment model can be developed in the future.

**Limitations**

This study was limited by its nature of retrospective study. There was a considerable amount of missing data, which might
lead to a relatively smaller sample size in performing logistic regression analysis on various independent risk factors. Due to its retrospectivity, patients with specific risk groups cannot be intentionally selected. In our case, we observed a skewed distribution of patients in terms of risk group (more than 90% of our patients are within the low risk group of 0-10%). In addition, Peterson et al. from the Duke Clinical Research Institute had looked into the association between surgeon experience and mortality post-CABG. It was shown that surgeon experience was a significant predictor of mortality. The highest mortality rate was observed when patients were treated by low-volume surgeons. This study was conducted in a cardiac centre with surgeons with varying levels of surgical experience. That might directly or indirectly affect the outcome of surgery or even in-hospital mortality to a certain extent.

**Conclusion**

This single centre large validation study showed that the EuroSCORE II exhibits reasonable and fair discriminatory power and calibration in predicting in-hospital mortality risk among patients undergoing CABG surgery in Malaysia. Despite being a single centre study and therefore may not be representative of the entire population, we think that it can be safely used as a risk assessment tool with cautious clinical consideration being applied on an individual basis.

**Data availability**

Raw data for the study ‘Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery in Malaysia’ are available both in excel and SAV formats. Data analysis is available in SPV format (SPSS output).

Dataset 1 – Demography and EuroScore II variables (Excel) 10.5256/f1000research.14760.d202216

Dataset 2 – Demography and EuroScore II variables (SPSS) 10.5256/f1000research.14760.d202216

Dataset 3 – SPSS Output 10.5256/f1000research.14760.d202217

**Ethics approval**

All research procedures were done in accordance with the ethical regulations set by the JIN ethics committee, Monash University Human Research Ethics Committee (MUHREC) and it abides with the Helsinki Declaration revised in 2013.

**Acknowledgement**

The authors would like to extend our gratitude to all the staff at the Research Department, National Heart Institute, especially Ms. Norfazlina Binti Jaffar, assistant manager of the data management & biostatistical support services, for their assistance in data collection.

**References**

1. Hannan EL, Racz MJ, Wallford G, et al.: Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2000; 352(21): 2174–2183. 
   *PubMed* | *Full Text*

2. Birkmeyer JD, Sievers AE, Finlayson EV, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med. 2002; 346(15): 1128–37. 
   *PubMed* | *Full Text*

3. Musa AF, Chao ZQ, Low ZX, et al.: Retrospective review on atrial fibrillation after coronary artery bypass grafting: a single centre experience. Paper presented at: 40th World Congress of the International College of Surgeons; 2016; Oct 23–26; Kyoto, JP. 
   *PubMed* | *Full Text*

4. Peterson ED, Combs LP, Delong ER, et al.: Procedural volume as a marker of quality for CABG surgery. JAMA. 2004; 291(5): 195–201. 
   *PubMed* | *Full Text*
methods for predicting survival--III. Accuracy of predictions in generating and challenge sets. J Clin Epidemiol. 1990; 43(4): 361–372.

24. Ranucci M, Castelvecchio S, Menicanti L, et al.: Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation. 2009; 119(24): 3053–3061.

25. Musa AF, Cheong XP, Dillon J, et al.: Dataset 1 in: Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review. F1000Research. 2018. http://www.doi.org/10.5256/f1000research.14760.d20221

26. Musa AF, Cheong XP, Dillon J, et al.: Dataset 2 in: Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review. F1000Research. 2018. http://www.doi.org/10.5256/f1000research.14760.d202216

27. Musa AF, Cheong XP, Dillon J, et al.: Dataset 3 in: Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review. F1000Research. 2018. http://www.doi.org/10.5256/f1000research.14760.d202217
Louise Y. Sun

1 Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
2 Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

Musa and colleagues validated the EuroSCORE II in a retrospective cohort of 1718 patients who underwent cardiac surgery at a single centre in Malaysia. They concluded that the EuroSCORE II had acceptable discrimination and calibration at this large centre.

Thank you for the opportunity to review this carefully constructed work. My comments mainly pertain to the clarity of reporting and the quality of data used:

1. Selection criteria: why exclude patients with repeat interventions during the same surgical admission? These patients would be at the highest risk for mortality, and including them may improve the predictiveness of the model.

2. The title and introduction suggest this study was about CABG patients. However, outcomes of “isolated CABG, isolated non-CABG, 2-procedures, 3-procedures, surgery on the thoracic aorta” were studied. In addition, why were patients who underwent isolated valve procedures not included?

3. Was the study data collected prospectively or retrospectively, and by whom? How accurate and reliable was the data? What was the degree of missingness, and how was this handled? Data quality could have an impact on the performance of the predictive model.

4. Statistical analysis: Do the authors mean multivariable (instead of “multiple”) logistic regression?

5. Looks like the weighted analysis is actually unweighted subgroup analysis.

6. Table 1 should also provide the characteristics of those who died vs. those who did not.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Big data, cardiac surgery, predictive modeling

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
regarding the sample that was analyzed in the work, considering that the majority of patients in the sample belong to classes I or II of the NYHA, and as you declare in the limitations, “more than 90% of our patients are within the low risk group of 0-10%”. Your work could have the advantage to be done in one single service, with the same quality of the surgery. Unfortunately, you said that the performance of the surgeons is not the same, between them.

Particularly, I have critiques about the multicenter studies, which have a lot of qualities, but the surgeons from different services and nations have different results, like you expressed in the limitations. The problem of the work being retrospective brings some problems, but this does not compromise the results.

Your discussion was very clear, adding your article in the present context of the literature. The conclusions are simple and straightforward, allowing the Cardiac Surgeons of Malaysia to use the EuroSCORE II, securely in your country.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cardiovascular Surgery, Emeritus Professor at FAMERP and UNICAMP. Editor in Chief of Brazilian Journal OF Cardiovascular Surgery [www.bjcvs.org]

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The authors have used same methodology as we did in our study. This is the usual standard.

1. Please share details of two and three procedures whether they were CABG AVR or CABG MVR or DVR!

2. It would be a better idea to analyse mortality in performance of Euroscore II for isolated CABG and combined procedure separately.

3. Table 3 there is concordance between expected and observed mortalities in subgroups 0-10% and 11-20%. However for >20% there is gross mismatch of expected and observed mortalities. Please share details of 8 patients who died in this group. Did they belong to isolated CABG category or the combined procedure? As suggested above, please separate analysis of performance of Euroscore II for isolated CABG and combined procedures. This will give a true picture of performance in these two distinct groups. It may also explain the reason for underestimation in >20% group and may even improve concordance within results.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Clinical outcome research

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 21 Jun 2018

Ahmad Farouk Musa, Monash University Malaysia, Bandar Sunway, Malaysia

Dear Prof Hasanat, thank you for your comments. My answers were detailed below accordingly.

1. Please share details of two and three procedures whether they were CABG AVR or CABG MVR or DVR

In our study, there are 160 patients who underwent a combination of two procedures, which included CABG + AVR, CABG + MVR as well as CABG + Aortic Root Replacement. For 33 patients who underwent three procedures, it included CABG+MVR+Aortic Root Replacement; CABG+MVR+AVR; as well as CABG + ASD Closure + Devega's Tricuspid Annuloplasty.

1. It would be a better idea to analyze mortality in the performance of Euroscore II for isolated CABG and combined procedure separately.

Thank you again for your suggestion. We have already performed subgroup analysis based on weightage of procedures. Among 1488 patients who underwent isolated CABG, we observed an actual in-hospital mortality rate of 3.9% and a median EuroSCORE II (predicted mortality) of 1.918, which showed an underestimation of risk. Hosmer and Lemeshow Goodness-of-Fit test showed a significant p value of 0.032, indicating a significant difference between expected and actual mortality among this group of patients. Discriminatory power as shown by the ROC curve analysis showed an area of 67.8%.

Among 160 patients who underwent two procedures, we observed an actual in-hospital mortality rate of 10% and a median EuroSCORE II (predicted mortality) of 3.712, which showed an underestimation of risk. However, Hosmer and Lemeshow Goodness-of-Fit test showed a non-significant p-value of 0.591, indicating no significant difference between expected and actual mortality among this group of patients. Discriminatory power as shown by the ROC curve analysis showed an area of 63.4%.

Lastly, among 33 patients who underwent three procedures, we observed an actual in-hospital mortality rate of 18.2% and a median EuroSCORE II (predicted mortality) of 6.2, which showed an underestimation of risk. Similar to two procedures, Hosmer and Lemeshow Goodness-of-Fit test showed a non-significant p-value of 0.575, indicating no significant difference between expected and actual mortality among this group of patients. Discriminatory power as shown by the ROC curve analysis showed an area of 67.9%.

1. Table 3 there is concordance between expected and observed mortalities in subgroups 0-10% and 11-20%. However, for >20% there is a gross mismatch between expected and observed mortalities. Please share details of 8 patients who died in this group. Did they belong to isolated CABG category or the combined procedure?

Among the 8 patients who died in the 11-20% subgroup, 4 of them had isolated CABG (50%), while 2 of them underwent two procedures (25%) and the other 2, three procedures (25%)
respectively.

**Competing Interests:** No competing interest.

---

## Comments on this article

### Version 1

**Author Response 28 May 2018**

**Ahmad Farouk Musa**, Monash University Malaysia, Bandar Sunway, Malaysia

Dear Prof Nezic. Thank you very much for your interest and constructive comments on our article. We have revisited the numbers and studies we cited.

Firstly, We are deeply sorry to inform that we have incorrectly arranged the sequence of statistics according to countries. The correct sequence will be as followed:

The mortality rate for Italy, Greece and Serbia will be 4.85%, 3% and 3.7% respectively.

Secondly, based on your reply, you have mentioned that the specific mortality rate for CABG surgery in your study was 2.31%, which we acknowledge. However, we have cited the "overall mortality rate" of 3.65% (which also included other combination cardiac surgeries) because we intended to make a comparison with our study population that not only comprised of isolated CABG but also combination cardiac surgeries, where CABG is the main component.

Lastly, we also acknowledged the fact that despite our study showing a non-significance in HL Goodness-Of-Fit test, expected to observed mortality ratio seemed to be higher (2.22), which showed higher mortality than it was predicted by EuroSCORE II. Therefore, we described this particular event in our discussion that there was an underestimation of risk by the EuroSCORE II in our group of patients based on our experience at the National Heart institute.

Thank you again for your comments and we appreciate it very much.

**Competing Interests:** No competing interests were disclosed.

---

**Reader Comment 20 May 2018**

**Dusko Nezic**, "Dedinje" Cardiovascular Institute, Belgrade, Serbia

I read with great interest the manuscript (1) by Ahmad Farouk Musa et al., regarding validation of
EuroSCORE II in patient undergoing CABG surgery at the National Heart Institute, Kuala Lumpur. Among other references, our manuscript (2) has been quoted (authors reference No 12) with in-hospital mortality of 4.85% in CABG surgery. I regret to inform the authors that their data about our manuscript are misleading. In quoted manuscript (2) we presented 1309 CABG patients, with predicted mortality of 2.39% (average EuroSCORE II value was 2.39%) and in-hospital mortality was 2.31% [not 4.85% as authors presented in their manuscript (1)]. In our manuscript discrimination was excellent (AUC = 0.81). The expected to observed (O/E) mortality ratio [much better statistical analysis to determine calibration ability of the model compared with Hosmer-Lemeshow (H-L) test] was 0.96, with 95% confidence interval of 0.58-1.34.

Although H-L test confirmed good calibration in authors manuscript (1), H-L test p=0.09, O/E mortality ratio, calculated from theirs data (in-hospital mortality rate of 4.7%, with median EuroSCORE II value of 2.06%), appears to be 2.22, with 95% CI in a range of 1.71-2.69, thus confirming significantly higher mortality than it was predicted by EuroSCORE II.

In another manuscript (3), with a cohort of 5228 CABG patients we confirmed excellent discriminative power of EuroSCORE II model (AUC = 0.84). Predicted mortality was 2.41%, and observed mortality was 2.24%. O/E mortality ratio was 0.93 with 95% CI of 0.76-1.10, thus confirming statistically nonsignificant overestimation of mortality by EuroSCORE II for CABG surgery in Serbian patients (in another words, calibration was good).

References
1. Musa AF, Cheong XP, Dillon J, Nordin RB. Validation of EuroSCORE II in patients undergoing coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review. F1000 Research 7:534
2. Nezic D, et al. Consecutive observational study to validate EuroSCORE II performances on a single-center, contemporary cardiac surgical cohort. J Cardiothorac Vasc Anesth 2016;30: 345–51.
3. Nezic D, et al. Clinical performances of EuroSCORE II risk stratification model in Serbian cardiac surgical population: a single centre validation study including 10048 patients. Vojnosanit Pregl 2018 (OnLine-First) doi.org/10.2298/VSP170810172N

**Competing Interests:** No competing interests were disclosed.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com